Iambic Therapeutics · 8 hours ago
Software Engineer II, Data
Iambic Therapeutics is a clinical-stage life-science and technology company developing novel medicines using its AI-driven discovery and development platform. They are seeking a Data Engineer to build and optimize data pipelines for AI model training, collaborating closely with ML engineers to enhance data workflows and performance.
Artificial Intelligence (AI)Machine LearningSoftwareTherapeutics
Responsibilities
Design and improve data pipelines that process large, multi-modal datasets from a variety of internal and external sources into training datasets for AI models
Evolve our data storage layer to support analytics, schema evolution, reproducibility, and efficient data access
Collaborate with ML engineers to improve the performance and reliability of Python-based data processing workflows
Qualification
Required
Minimum of 8 years of related experience with a Bachelor's degree; or 6 years and a Master's degree; or a PhD with 3 years experience; or equivalent experience
Proven ability to design flexible, maintainable ETL systems
Experience with data pipeline orchestration tools such as Prefect, Airflow, Argo, Databricks, or Spark
Hands-on experience with multi-terabyte scale data processing
Knowledge of data lake technologies such as Parquet, Iceberg, AWS Glue etc
Strong Python software engineering skills
Pragmatic mindset — able to evaluate tradeoffs find solutions that empower ML researchers to move quickly
Preferred
Familiarity with AWS
Kubernetes experience is a bonus
Understanding of the ML model lifecycle; prior work with scientific or ML workflows is a plus
Background in bioinformatics or chemistry is a plus
Benefits
Company paid healthcare
Flexible spending accounts
Voluntary life insurance
401K matching
Uncapped vacation
Company
Iambic Therapeutics
Iambic is a clinical-stage life-science and technology company developing novel medicines using its AI-driven discovery and development platform.
Funding
Current Stage
Growth StageTotal Funding
$303M2025-11-10Series Unknown· $100M
2024-04-24Series B· $50M
2023-10-03Series B· $100M
Recent News
2025-12-16
2025-11-30
Company data provided by crunchbase